
Science recap: This week's discoveries include the fossilized skull of a mysterious, prehistoric human species
Hundreds of Neanderthal fossils give us a good idea of their appearance, lives and relationships, but so little is known about Denisovans that they still don't have an official scientific name.
Evidence of their existence has surfaced in faint traces, mapped by DNA markers that lurk in our own genetic makeup and confirmed by only a few fossil fragments.
This week, however, a 146,000-year-old skull dredged out of a well in China in 2018 may just be a key missing piece to this cryptic evolutionary puzzle.
A long time ago
The nearly complete skull did not match any previously known species of prehistoric human.
But two new studies — which researchers say are among the biggest paleoanthropology papers of the year — detail how scientists were able to extract genetic material from the fossil and help unravel this biological mystery.
The DNA sample taken from 'Dragon Man,' as the specimen is called, revealed that he was in fact related to Denisovans, early humans who are thought to have lived between roughly 500,000 and 30,000 years ago.
The finding could be monumental, helping to paint a fuller picture of a time when our own species coexisted with other prehistoric humans.
Across the universe
Astronomers have long grappled with the quandary of 'dark matter,' but plenty of enigmas surround regular matter as well.
The proton-and-neutron-based atoms that we're familiar with are called baryonic matter. And this material is strewn between galaxies like intergalactic fog, making it extremely difficult to measure.
Perhaps, that is, until now.
A new study explains how scientists were able to observe the baryonic matter using the flashing of fast radio bursts.
In a rare encounter, scientists have captured the first-ever footage of an elusive 3-foot-long squid alive in its deep-sea habitat.
Unearthed
Fruit, flowers, birds and musical instruments decorated the walls of a luxury villa — part of a site the excavation team dubbed the 'Beverly Hills' of Roman Britain — before the building was razed roughly 1,800 years ago.
The frescoes were painstakingly pieced together by experts from the Museum of London Archaeology. Han Li, senior building material specialist at MOLA, described the effort as a 'once in a lifetime' opportunity.
Romans invaded modern-day Britain in AD 43 and established Londinium, the precursor to modern London. The occupation lasted for almost 400 years.
Curiosities
Under the life-affirming glow of the sun, methane is a dangerous gas to be avoided.
A heat-trapping chemical pollutant in Earth's atmosphere, methane exacerbates the climate crisis. But within the planet's deep recesses — thousands of feet below the ocean's surface off the US West Coast — the gas can be transformed into a nutritious meal.
At least for spiders.
Scientists say they've discovered three previously unknown species of sea spider living around methane seeps. In these marine habitats where sunlight can't reach, gas escapes through cracks in the seafloor and feeds bacteria that latch on to the spiders' exoskeletons.
The bacteria convert carbon-rich methane and oxygen into sugars and fats the spiders can eat, according to a new study.
The newfound Sericosura sea spiders may pass methane-fueled bacteria to their hatchlings as an easy source of food, the researchers suggest.
Take note
Check out these other must-read science stories from the week:
— A SpaceX Starship rocket exploded during a routine ground test on Wednesday. Explore how this and other recent setbacks may affect the company's Mars ambitions.
— A tiny brown moth in Australia migrates some 600 miles at night using the stars for navigation — something only humans and birds were known to do before.
— A hunt for ghostly cosmic particles found anomalous signals coming from Antarctic ice. A new detector could help scientists explain what they are.
— Researchers used DNA to reconstruct the face of a prehistoric woman who lived around 10,500 years ago in what's now Belgium, suggesting that skin color already varied considerably among different populations.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CNN
3 minutes ago
- CNN
CNN10 How A.I. is being used by police departments
Today on CNN10: We discuss what we know about a dangerous steel plant explosion in Pennsylvania, before explaining why the U.S. and China are pressing pause on their tariff hikes,. Then, we see how A.I. is being tested to help some police departments write reports. We'll head to the South China Sea, where two Chinese military ships have collided, and dive into the discovery of a starfish with, well… a surprisingly large backside. All this and more on today's CNN10!
Yahoo
2 hours ago
- Yahoo
Expedition, a startup searching for drugs from China, cuts its first deal
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. A stealthy biotechnology startup has agreed to pay potentially hundreds of millions of dollars for an experimental medicine from Fosun Pharma, adding to a flurry of dealmaking involving drugs discovered in Chinese laboratories. The startup, Expedition Therapeutics, will pay Fosun up to $120 million in upfront cash and development milestones for rights outside of mainland China, Hong Kong and Macau, to a drug codenamed XH-S004. Expedition could hand Fosun up to $525 million more if the drug is approved and hits certain sales targets, the companies said Monday. The deal is the first public announcement so far involving Expedition, a secretive startup incorporated in Delaware last year and backed by Venrock, BVF and Lake Bleu Capital, according to its LinkedIn page. The company is run by Yi Larson, a former Goldman Sachs banker who's held either executive or board positions with Turning Point Therapeutics, LianBio and RayzeBio. Expedition aims to in-license assets from China, a strategy that makes it part of a growing trend in biotech startup creation. The company is one of at least seven companies formed since the start of last year being built around China-originated drugs, according to data collected by BioPharma Dive. Several, such as Candid Therapeutics, Kailera Therapeutics and Ouro Medicines, debuted with funding rounds exceeding $100 million. The proliferation of these new companies has been spurred by fast progress from China's biotech sector. Large pharmaceutical firms have taken notice, inking dozens of deals with China-based companies that, according to the investment bank Jefferies, accounted for about one-fifth of the industry's licensing spending in 2024 and one-third in the first half of this year. On its LinkedIn page, Expedition says it has 'strong visibility into [the] competitive landscape of both U.S. and China biotech ecosystems' as well as an 'extensive knowledge and network of relationships with innovator companies across China.' Its first deal is for a small molecule drug that targets DPP-1, an enzyme linked to the development and progression of multiple inflammatory conditions. DPP-1 is the target of brensocatib, a drug AstraZeneca discovered and licensed to Insmed a decade ago that's since been tested in multiple lung conditions. It succeeded in Phase 3 testing against one of those diseases, bronchiectasis, last year. U.S. regulators cleared it on Tuesday, making brensocatib, now known as Brinsupri, the first drug of its type to get to market. Fosun's drug is currently in Phase 2 testing in China for bronchiectasis and in earlier-stage testing for chronic obstructive pulmonary disease. 'XH-S004 is an exciting compound that targets neutrophilic inflammation, an important underlying driver of a number of chronic respiratory diseases,' Larson said in a statement.'We look forward to partnering with Fosun Pharma in the development of XH-S004 for COPD and other neutrophilic inflammatory diseases to address the significant unmet medical need.' Editor's note: This story has been updated with details about the approval of Brinsupri. Sign in to access your portfolio


Forbes
2 hours ago
- Forbes
In The AI Age, Even Honest Workers May Face A 'Competence Penalty'
Workers who are using AI to do their job are rated as less competent than those who are not, even if the AI users are transparent about their methods, and even if the quality of the work done with AI is identical to the quality of that done without, new research suggests. Four academics, from King's Business School in London, Peking University, the Hong Kong Polytechnic University, and University of Hong Kong conducted an experiment in which they got 1,026 engineers to evaluate a Python code snippet that was written by another engineer—either with or without help from AI. In every case the code itself was identical; only the described method of creation differed from sample to sample. Yet when reviewing engineers believed that an engineer had used AI to write the code, they rated that engineer's competence an average of 9% lower. Perhaps even more striking: this competence penalty was more than twice as harsh for female engineers than it was for male engineers. Indeed, the women in the study faced a 13% reduction compared to the 6% reduction suffered by their male counterparts. 'When reviewers thought a woman had used AI to write code,' the researchers explained in the Harvard Business Review, 'they questioned her fundamental abilities far more than when reviewing the same AI-assisted code from a man.' The penalties also varied significantly depending on the evaluator. Engineers who had not adopted AI themselves were the harshest critics—especially male non-adopters evaluating female engineers. In those cases, they penalized women 26% more than men for the exact same AI usage. Reflecting on their findings, the researchers noted that they reveal a 'hidden tax' on AI adoption. 'What looks like simple reluctance to use new tools actually reflects rational self-preservation. The true cost extends far beyond lost productivity—although productivity losses alone can also be substantial,' they wrote. It also casts a fresh light on the gender gaps that permeate the evolving workforce—from trust to perceived competency—and underscores the risks of new technologies exacerbating existing inequalities, such as pay gaps.